ArticleSexually transmitted diseases2025
Clinical and Sociodemographic Factors Associated With Ocular Mpox in California, May 2022 to September 2023.
Article in Sexually transmitted diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An integrated review of monkeypox: from pathogen and epidemiology to diagnostics, control, and challenges.Emerging microbes & infections · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundInoculation of the eye with monkeypox virus can cause vision-threatening disease necessitating hospitalization and urgent treatment. Ocular mpox is poorly understood, including who is most affected.
methodsWe performed a cross-sectional study comparing ocular and non-ocular mpox cases reported to the California Department of Public Health from May 1, 2022, to September 30, 2023. χ2 and t tests were used to compare between-group sociodemographic characteristics, HIV status, and vaccine status. Bivariate and multivariate logistic regressions adjusting for HIV and race/ethnicity were used to calculate odds ratios and 95% confidence intervals for the association between JYNNEOS vaccination and ocular mpox.
resultsOf 5878 mpox infections, 2403 (40.9%) had complete ocular symptom reporting and were included in this analysis. Of these, 260 (10.8%) were ocular cases. Among the 2403 included cases, most were cisgender men (94.6%) and reported male-to-male sexual contact (72.0%). The proportion of non-ocular versus ocular mpox cases differed significantly by race/ethnicity and HIV status ( P < 0.05), with more ocular cases being Hispanic/Latinx (50.8% vs. 41.8%), Black (14.2% vs. 8.9%), and with HIV (50.8% vs. 40.4%). After adjusting for race/ethnicity and HIV status, people with ≥1 dose of JYNNEOS had approximately half the odds of having ocular symptoms compared with people who were unvaccinated (adjusted odds ratio, 0.52; 95% confidence interval, 0.24-0.97).
conclusionsA higher proportion of Black, Latinx, or people living with HIV had ocular mpox symptoms, suggesting that these groups may benefit from focused interventions to prevent infection and this complication. JYNNEOS before mpox exposure may protect against ocular complications, stressing the importance of vaccination to prevent severe sequelae, especially for vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.